Results for tag: "Xospata"

Xospata (generic name: gilteritinib) is a targeted therapy drug used to treat adults with relapsed or refractory acute myeloid leukemia (AML). It is a type of kinase inhibitor, which works by blocking certain proteins that help cancer cells grow and divide. Xospata is approved by the U.S. Food and Drug Administration (FDA) for use in adults with relapsed or refractory AML who have a specific genetic mutation called FLT3. Xospata is the first and only FDA-approved targeted therapy for this type of AML. Xospata is a relatively new drug in the leukemia drug market, and is part of a growing trend of targeted therapies for AML. These therapies are designed to target specific genetic mutations that are associated with the disease, and are often more effective than traditional chemotherapy. The Xospata market is highly competitive, with several major pharmaceutical companies vying for market share. These include Astellas Pharma, Daiichi Sankyo, Novartis, and Pfizer. Other companies, such as Celgene, are also developing drugs for the treatment of AML. Show Less Read more